Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,364 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Syringe Clear all
Completed Phase 3 Interventional Results available

Phase IIIB Subcutaneous Missed Dose Study

NCT00533897
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Trumbull, Connecticut • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 28, 2026, 4:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Blood Gas Syringes

NCT01935284
View directory record Official record
Conditions
Blood Gas Analyte Values
Interventions
Not listed
Lead sponsor
Smiths Medical, ASD, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Devens, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 28, 2026, 4:01 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

"Loss of Resistance" Versus CompuFlo® for Epidural Placement

NCT00178750
View directory record Official record
Conditions
Pain, Epidural Analgesia
Interventions
18G Tuohy epidural needle, CompuFlo® computerized syringe pump
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

NCT01535950
View directory record Official record
Conditions
Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
Interventions
LFG316, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Tucson, Arizona • Torrance, California • Fort Myers, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 28, 2026, 4:01 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Arcadia, California • Los Angeles, California • Newport Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 4:01 PM EDT
Terminated Phase 3 Interventional

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

NCT06307626
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

NCT00552344
View directory record Official record
Conditions
Crohn Disease
Interventions
Cimzia
Biological
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
20
States / cities
Lakewood, Colorado • Littleton, Colorado • New Port Richey, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 28, 2026, 4:01 PM EDT
Completed No phase listed Observational

Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents

NCT01737554
View directory record Official record
Conditions
Cancer, Hematologic Disorders
Interventions
Catheter Resistance Monitoring
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years to 24 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Oct 28, 2026, 4:01 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05769153
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
42
States / cities
Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Sling vs Botox for Mixed Incontinence

NCT04171531
View directory record Official record
Conditions
Urinary Incontinence, Stress, Urinary Incontinence, Urge
Interventions
Botox® injection, Mid-urethral sling
Drug · Device
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 28, 2026, 4:01 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study

NCT06085079
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
Ixekizumab Prefilled Syringe
Drug
Lead sponsor
Massachusetts Eye Research and Surgery Institution
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 28, 2026, 4:01 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination

NCT06007183
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
CHIKV VLP vaccine booster, Placebo booster
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
12 Years and older
Enrollment
715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
24
States / cities
Mobile, Alabama • Tempe, Arizona • Melbourne, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis

NCT02696031
View directory record Official record
Conditions
Non-radiographic Spondyloarthritis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Fullerton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 28, 2026, 4:01 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD

NCT02515669
View directory record Official record
Conditions
Muscular Dystrophy (DMD)
Interventions
RO7239361, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 10 Years · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Not applicable Interventional Results available

Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent

NCT02080312
View directory record Official record
Conditions
Meniere's Disease
Interventions
Magnevist (gadopentetate dimeglumine)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Caverject User Study

NCT01008605
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
delivery system
Other
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 70 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 28, 2026, 4:01 PM EDT
Recruiting Phase 3 Interventional

Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

NCT07444567
View directory record Official record
Conditions
Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
Interventions
Benralizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Aurora, Colorado • Bethesda, Maryland • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 4:01 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

NCT03416335
View directory record Official record
Conditions
Neoplasms
Interventions
DSP-0509, DSP-0509, Pembrolizumab
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Indianapolis, Indiana • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 4 Interventional Results available

Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures

NCT05294640
View directory record Official record
Conditions
Eyelid Tumor, Eyelid Bump, Eyelid Deformity, Eyelid Abscess, Eyelid Boil, Eyelid Papilloma, Anesthesia, Local, Ophthalmology
Interventions
0.9% Bacteriostatic Local Anesthetic Injection, 1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection, Eyelid Lesion Removal
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 110 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 28, 2026, 4:01 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

NCT07647510
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
Claseprubart, Placebo, Claseprubart, Placebo
Drug · Combination Product
Lead sponsor
Dianthus Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Pasadena, California • Boca Raton, Florida • Fayetteville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Combination of Magnesium and Lidocaine for the Pretreatment of Pain That is Caused by the Injection of Propofol

NCT01342510
View directory record Official record
Conditions
General Anesthesia, Intravenous Anesthesia
Interventions
Magnesium Sulfate, Lidocaine, Control, Lidocaine/Magnesium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries

NCT01754480
View directory record Official record
Conditions
Parenchymous Tissue Surgical Bleeding
Interventions
Fibrin Sealant Grifols, Surgicel®
Biological · Device
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Not listed
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
26
States / cities
Loma Linda, California • Los Angeles, California • New Haven, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

NCT05817435
View directory record Official record
Conditions
Bioequivalence
Interventions
efgartigimod PH20 SC as a prefilled syringe presentation, efgartigimod PH20 SC as a vial + syringe presentation
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 28, 2026, 4:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

NCT03895385
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 28, 2026, 4:01 PM EDT